Search

Your search keyword '"Zamagni E"' showing total 21 results
Start Over Author "Zamagni E" Publisher elsevier bv
21 results on '"Zamagni E"'

3. Efficacy and safety of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment: results of the phase 2 dare study

Author

Terpos, E., primary, Symeonidis, A., additional, Delimpasi, S., additional, Zamagni, E., additional, Katodritou, E., additional, Rivolti, E., additional, Kyrtsonis, M., additional, Fotiou, D., additional, Kanellias, N., additional, Migkou, M., additional, Roussou, M., additional, Gavriatopoulou, M., additional, Hatjiharissi, E., additional, Cavo, M., additional, and Dimopoulos, M., additional

Published
2020
Full Text
View/download PDF

4. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Author

Moreau, P., primary, San Miguel, J., additional, Sonneveld, P., additional, Mateos, M.V., additional, Zamagni, E., additional, Avet-Loiseau, H., additional, Hajek, R., additional, Dimopoulos, M.A., additional, Ludwig, H., additional, Einsele, H., additional, Zweegman, S., additional, Facon, T., additional, Cavo, M., additional, Terpos, E., additional, Goldschmidt, H., additional, Attal, M., additional, and Buske, C., additional

Published
2017
Full Text
View/download PDF

5. A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis

Author

Kastritis, E., primary, Leleu, X., additional, Arnulf, B., additional, Zamagni, E., additional, Cibeira, M.T., additional, Kwok, F., additional, Mollee, P., additional, Hájek, R., additional, Moreau, P., additional, Jaccard, A., additional, Schönland, S., additional, Filshie, R., additional, Nicolas-Virelizier, E., additional, Augustson, B., additional, Mateos, M.-V., additional, Wechalekar, A., additional, Hachulla, E., additional, Milani, P., additional, Dimopoulos, M.A., additional, Fermand, J.-P., additional, Foli, A., additional, Gavriatopoulou, M., additional, Palumbo, A., additional, Sonneveld, P., additional, Johnsen, H.E., additional, Merlini, G., additional, and Palladini, G., additional

Published
2015
Full Text
View/download PDF

6. Hedgehog Pathway Over Expression Identifies Myeloma Patients With Worse Prognosis

Author

Martello, M., primary, Remondini, D., additional, Pezzi, A., additional, Borsi, E., additional, Procacci, M., additional, Dico, A.F., additional, Santacroce, B., additional, Pantani, L., additional, Zamagni, E., additional, Tacchetti, P., additional, Rocchi, S., additional, Zannetti, B.A., additional, Marzocchi, G., additional, Testoni, N., additional, Martinelli, G., additional, Cavo, M., additional, and Terragna, C., additional

Published
2015
Full Text
View/download PDF

7. Rare High Risk IgH Translocations in Newly Diagnosed Multiple Myeloma (MM): Cytogenetic Characterization and Relevance on Prognosis

Author

Marzocchi, G., primary, Testoni, N., additional, Ameli, G., additional, Pezzi, A., additional, Zamagni, E., additional, Cavallo, F., additional, Petrucci, M.T., additional, Waage, A., additional, Di Raimondo, F., additional, Patriarca, F., additional, Pantani, L., additional, Luatti, S., additional, Rambaldi, A., additional, Gamberi, B., additional, Crippa, C., additional, Zweegman, S., additional, Montefusco, V., additional, Baldazzi, C., additional, Vincelli, I., additional, Offidani, M., additional, Palumbo, A., additional, Sonneveld, P., additional, and Cavo, M., additional

Published
2015
Full Text
View/download PDF

11. A451 Superiority of VTD over TD Incorporated Into ASCT for Newly Diagnosed MM

Author

Cavo, M, primary, Zambello, R, additional, Nozzoli, C, additional, Gugliotta, L, additional, Pantani, L, additional, Patriarca, F, additional, Petrucci, MT, additional, Tacchetti, P, additional, Galli, M, additional, Ceccolini, M, additional, Di Raimondo, F, additional, Rossi, G, additional, Zamagni, E, additional, Bringhen, S, additional, Narni, F, additional, Tosi, P, additional, Montefusco, V, additional, Offidani, M, additional, Brioli, A, additional, Pallotti, MC, additional, Spadano, T, additional, Pescosta, N, additional, Goldaniga, M, additional, Ledda, A, additional, Perrone, G, additional, Petrucci, A, additional, Caravita, T, additional, Cascavilla, N, additional, Gherlinzoni, F, additional, De Stefano, V, additional, Angelucci, E, additional, Petti, MC, additional, Ballanti, S, additional, Callea, V, additional, and Baccarani, M, additional

Published
2009
Full Text
View/download PDF

13. A141 Enoxaparin Versus Aspirin Versus Low-Fixed-Dose Warfarin in MM Patients Treated Up Front with Thalidomide

Author

Palumbo, A, primary, Cavo, M, additional, Bringhen, S, additional, Patriarca, F, additional, Petrucci, MT, additional, Offidani, M, additional, Galli, M, additional, Marasca, R, additional, Ria, R, additional, Nozzoli, C, additional, Crippa, C, additional, Baldini, L, additional, Callea, V, additional, Pescosta, N, additional, Rizzo, M, additional, Zamagni, E, additional, Brioli, A, additional, Di Raimondo, F, additional, Gaidano, G, additional, and Boccadoro, M, additional

Published
2009
Full Text
View/download PDF

14. B497 Pathways Shared by t(4;14) and D13 positive MM Patients Impact Response to Velcade/Thalidomide/Dexamethasone

Author

Terragna, C, primary, Marzocchi, G, additional, Renzulli, M, additional, Zamagni, E, additional, Durante, S, additional, Astolfi, A, additional, Testoni, N, additional, Tacchetti, P, additional, Tosi, P, additional, Ceccolini, M, additional, Pantani, L, additional, Martinelli, G, additional, Baccarani, M, additional, and Cavo, M, additional

Published
2009
Full Text
View/download PDF

16. Daratumumab-Based Therapy for IgM Multiple Myeloma With Hyperviscosity Syndrome: A Case Report

Author

Roberto Mina, Francesca Bonello, Francesca Gay, Elena Zamagni, Mario Boccadoro, Mina R., Bonello F., Gay F., Zamagni E., and Boccadoro M.

Subjects
Oncology, Cancer Research, medicine.medical_specialty, IgM, business.industry, medicine.medical_treatment, Hyperviscosity syndrome, Daratumumab, Plasmapheresis, Hematology, medicine.disease, Multiple myeloma, Internal medicine, Medicine, business
Abstract

NA

Published
2021
Full Text
View/download PDF

17. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study

Author

Paola Tacchetti, Lucia Pantani, Francesca Patriarca, Maria Teresa Petrucci, Elena Zamagni, Luca Dozza, Monica Galli, Francesco Di Raimondo, Claudia Crippa, Mario Boccadoro, Simona Barbato, Patrizia Tosi, Franco Narni, Vittorio Montefusco, Nicoletta Testoni, Antonio Spadano, Carolina Terragna, Norbert Pescosta, Giulia Marzocchi, Claudia Cellini, Piero Galieni, Sonia Ronconi, Marco Gobbi, Lucio Catalano, Antonio Lazzaro, Giovanni De Sabbata, Clotilde Cangialosi, Fabrizio Ciambelli, Pellegrino Musto, Francesca Elice, Michele Cavo, Renato Fanin, Roberto Foa', Alessandro Rambaldi, Giuseppe Rossi, Pietro Leoni, Paolo Corradini, Giuseppe Torelli, Giuseppe Fioritoni, Sergio Cortelazzo, Giorgio Lambertenghi Deliliers, Giorgio La Nasa, Alfonso Zaccaria, Paolo De Fabritiis, Nicola Cascavilla, Alberto Bosi, Gianpietro Semenzato, Luigi Gugliotta, Filippo Gherlinzoni, Emanuele Angelucci, Massimo Fabrizio Martelli, Maria Concetta Petti, Giuseppe Leone, Angelo Michele Carella, Fabio Ciceri, Armando Santoro, Felicetto Ferrara, Francesco Nobile, Alfonso Maria D'Arco, Alessandro Levis, Luciano Guardigni, Andrea Gallamini, Pier Paolo Fattori, Sergio Morandi, Dino Amadori, Bruno Rotoli, Salvatore Mirto, Giorgio Paladini, Ruggero Mozzana, Graziella Pinotti, Francesco Rodeghiero, Nicola Cantore, Vincenzo Pavone, Enrico Maria Pogliani, Anna Marina Liberati, Ignazio Majolino, Sergio Amadori, Francesco Lauria, Massimo Aglietta, Giovanni Quarta, Sergio Storti, Fortunato Morabito, Silvana Franca Capalbo, Alessandro Massimo Gianni, Vincenzo Mettivier, Vittorio Rizzoli, Carlo Bernasconi, Giuseppe Visani, Michele Pizzuti, Giacinto La Verde, Giuseppe Avvisati, Maurizio Longinotti, Eugenio Gallo, Franco Dammacco, Domenico Russo, Andrea Bacigalupo, Caterina Musolino, Tacchetti P., Pantani L., Patriarca F., Petrucci M.T., Zamagni E., Dozza L., Galli M., Di Raimondo F., Crippa C., Boccadoro M., Barbato S., Tosi P., Narni F., Montefusco V., Testoni N., Spadano A., Terragna C., Pescosta N., Marzocchi G., Cellini C., Galieni P., Ronconi S., Gobbi M., Catalano L., Lazzaro A., De Sabbata G., Cangialosi C., Ciambelli F., Musto P., Elice F., Cavo M., Fanin R., Foa' R., Rambaldi A., Rossi G., Leoni P., Corradini P., Torelli G., Fioritoni G., Cortelazzo S., Lambertenghi Deliliers G., La Nasa G., Zaccaria A., De Fabritiis P., Cascavilla N., Bosi A., Semenzato G., Gugliotta L., Gherlinzoni F., Angelucci E., Martelli M.F., Petti M.C., Leone G., Carella A.M., Ciceri F., Santoro A., Ferrara F., Nobile F., D'Arco A.M., Levis A., Guardigni L., Gallamini A., Fattori P.P., Morandi S., Amadori D., Rotoli B., Mirto S., Paladini G., Mozzana R., Pinotti G., Rodeghiero F., Cantore N., Pavone V., Pogliani E.M., Liberati A.M., Majolino I., Amadori S., Lauria F., Aglietta M., Quarta G., Storti S., Morabito F., Capalbo S.F., Gianni A.M., Mettivier V., Rizzoli V., Bernasconi C., Visani G., Pizzuti M., La Verde G., Avvisati G., Longinotti M., Gallo E., Dammacco F., Russo D., Bacigalupo A., and Musolino C.

Subjects
Adult, Male, medicine.medical_specialty, Transplantation Conditioning, Adolescent, Phases of clinical research, Transplantation, Autologous, Dexamethasone, Bortezomib, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, GIMEMA-MMY-3006 trial, bortezomib, thalidomide, dexamethasone, VTD, double autologous haematopoietic stem-cell transplantation, multiple myeloma, Multiple myeloma, Aged, Intention-to-treat analysis, business.industry, Hazard ratio, Hematopoietic Stem Cell Transplantation, Hematology, Middle Aged, medicine.disease, Thalidomide, Transplantation, Regimen, 030220 oncology & carcinogenesis, Female, Multiple Myeloma, business, Follow-Up Studies, 030215 immunology, medicine.drug
Abstract

Background: The phase 3 GIMEMA-MMY-3006 trial, which compared bortezomib, thalidomide, and dexamethasone (VTD) combination therapy with thalidomide and dexamethasone (TD) as induction therapy before and consolidation therapy after double autologous haematopoietic stem-cell transplantation (HSCT) for newly diagnosed multiple myeloma, showed the superiority of the triplet regimen over the doublet in terms of increased complete response rate and improved progression-free survival. We report the results from the final analysis of the study. Methods: In this randomised, open-label, phase 3 study, patients aged 18–65 years with previously untreated symptomatic multiple myeloma and a Karnofsky Performance Status of 60% or higher were enrolled at 73 centres in Italy. Patients were randomised (1:1) by a web-based system to receive three 21-day cycles of thalidomide (100 mg daily orally for the first 14 days and 200 mg daily thereafter) plus dexamethasone (total 320 mg per cycle; 40 mg on days 1–2, 4–5, 8–9, and 11–12 in the VTD regimen, and 40 mg on days 1–4 and 9–12 in the TD regimen), either alone (TD group) or with bortezomib (1·3 mg/m2 intravenously on days 1, 4, 8, and 11; VTD group). After double autologous HSCT, patients received two 35-day cycles of either the VTD or TD regimen, according to random assignment, as consolidation therapy. The primary outcome was the rate of complete response and near complete response after induction (already reported). In this updated analysis we assessed long-term progression-free survival and overall survival (secondary endpoints of the study) with an extended 10-year median follow-up, and analysed the variables influencing survival. Analysis was by intention to treat. The study is registered with ClinicalTrials.gov, NCT01134484. Findings: Between May 10, 2006, and April 30, 2008, 480 patients were enrolled and randomly assigned to receive VTD (241 patients) or TD (239 patients). Six patients withdrew consent before start of treatment. 236 (99 [42%] women) in the VTD group and 238 (102 [43%] women) in the TD group were included in the intention-to-treat analysis. The data cutoff date for this analysis was May 31, 2018. Median follow-up for surviving patients was 124·1 months (IQR 117·2–131·7). The 10-year progression-free survival estimate for patients in the VTD group was 34% (95% CI 28–41) compared with 17% (13–23) for the TD group (hazard ratio [HR] 0·62 [95% CI 0·50–0·77]; p

Published
2020
Full Text
View/download PDF

18. Expanding CD38-targeting triplets for relapsed or refractory multiple myeloma

Author

Paola Tacchetti, Elena Zamagni, Michele Cavo, Cavo M., Tacchetti P., and Zamagni E.

Subjects
Oncology, medicine.medical_specialty, business.industry, MEDLINE, Refractory Multiple Myeloma, General Medicine, CD38, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Text mining, Internal medicine, medicine, Humans, Multiple Myeloma, business, Human
Abstract

na

Published
2021
Full Text
View/download PDF

19. Fluorodeoxyglucose-PET/Computed Tomography as a Predictor of Prognosis in Multiple Myeloma

Author

Cristina Nanni, Elena Zamagni, Nanni C., and Zamagni E.

Subjects
medicine.medical_specialty, Prognosi, Predictive Value of Test, Standardized uptake value, Computed tomography, Disease, 030218 nuclear medicine & medical imaging, Fluorodeoxyglucose PET, 03 medical and health sciences, 0302 clinical medicine, Fluorodeoxyglucose F18, Predictive Value of Tests, Positron Emission Tomography Computed Tomography, medicine, Humans, Radiology, Nuclear Medicine and imaging, F FDG-PE/CT, Multiple myeloma, Extramedullary disease, Fluorodeoxyglucose, Radiation, medicine.diagnostic_test, business.industry, General Medicine, Prognosis, medicine.disease, Treatment Outcome, 030220 oncology & carcinogenesis, Predictive value of tests, Radiology, Radiopharmaceuticals, Multiple Myeloma, business, Human, medicine.drug
Abstract

Fluorodeoxyglucose-PET/CT is a valuable tool for the work-up of patients with newly diagnosed and relapsed/refractory multiple myeloma, because it assesses bone damage with high sensitivity and specificity and detects extramedullary sites of proliferating clonal plasma cells (extramedullary diseases). PET/CT provides valuable prognostic data at diagnosis and at restaging during the course of the disease. Consistencies between independent studies confirm the negative prognostic value of extramedullary disease and greater than 3 focal lesions, whereas the role of standardized uptake value is more conflicting. Standardization of the technique is ongoing.

Published
2019
Full Text
View/download PDF

20. Role of Consolidation Therapy in Transplant Eligible Multiple Myeloma Patients

Author

Michele Cavo, Annamaria Brioli, Ba Zannetti, Katia Mancuso, Elena Zamagni, Paola Tacchetti, Cavo M, Brioli A, Tacchetti P, Zannetti BA, Mancuso K, and Zamagni E.

Subjects
Oncology, medicine.medical_specialty, Transplantation, Autologous, Bortezomib, Consolidation therapy, Maintenance therapy, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Lenalidomide, Multiple myeloma, CONSOLIDATION, Clinical Trials as Topic, business.industry, Consolidation Chemotherapy, Hematology, medicine.disease, Boronic Acids, Thalidomide, Surgery, Transplantation, Treatment Outcome, Pyrazines, Multiple Myeloma, business, Stem Cell Transplantation, medicine.drug
Abstract

The role of high-dose therapy and autologous stem-cell transplantation (ASCT) in the treatment of multiple myeloma (MM) has continued to evolve in recent years. The novel agents thalidomide, bortezomib, and lenalidomide have been successfully incorporated into induction therapy in preparation for ASCT and are currently being investigated also as post-ASCT consolidation and maintenance therapy. Consolidation treatment is generally short term and aims to increase the frequency and depth of response obtained with the previous treatment phases, including novel agent-based induction therapy and ASCT. This review will focus on recent trials of novel agents as post-ASCT consolidation therapy, offering an overview of pros and cons of this new treatment strategy in the ASCT sequence for MM patients.

Published
2013
Full Text
View/download PDF

21. Thalidomide-Dexamethasone as Induction Therapy before Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma and Renal Insufficiency

Author

Alessandro Petrucci, Michele Baccarani, Lucia Pantani, Patrizia Tosi, Michela Ceccolini, Michele Cavo, Annamaria Brioli, Elena Zamagni, Maria Caterina Pallotti, Giulia Perrone, Paola Tacchetti, Tosi P, Zamagni E, Tacchetti P, Ceccolini M, Perrone G, Brioli A, Pallotti MC, Pantani L, Petrucci A, Baccarani M, and Cavo M.

Subjects
Male, Autologous transplantation, medicine.medical_specialty, Urology, Renal function, Myeloma, Transplantation, Autologous, Dexamethasone, Disease-Free Survival, Autologous stem-cell transplantation, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Renal Insufficiency, Multiple myeloma, Aged, Peripheral Blood Stem Cell Transplantation, Transplantation, Bortezomib, business.industry, Remission Induction, Hematopoietic Stem Cell Transplantation, Hematology, Middle Aged, medicine.disease, Combined Modality Therapy, Surgery, Thalidomide, Female, business, Multiple Myeloma, medicine.drug
Abstract

The aim of this study was to evaluate the efficacy and the toxicity of thalidomide-dexamethasone (Thal-Dex) as induction therapy before autologous peripheral blood stem cell (PBSC) transplantation in patients with newly diagnosed multiple myeloma (MM) with renal insufficiency. The study included 31 patients with a baseline creatinine clearance valueor=50 mL/min, 7 of whom required chronic hemodialysis. Patients received 4 months of Thal-Dex, followed by PBSC collection and subsequent transplantation. After induction, a partial response (PR) or greater was obtained in 23 patients (74%), including 8 (26%) who achieved a very good PR. Renal function improved more frequently in patients achieving a PR or greater (82%, vs 37% in patients achieving less than a PR; P = .04). Twenty-six patients underwent PBSC mobilization; in 17 of these patients (65%),4 x 10(6) CD34(+) cells/kg were collected. Double autologous transplantation was performed in 15 patients, and a single autologous transplantation was performed in 7 patients. After a median of 32 months of follow-up, median event-free survival was 30 months, and median survival was not determined. According to our data, Thal-Dex is effective and safe in patients with newly diagnosed MM and renal insufficiency. Given the relationship between recovery of renal function and response to induction treatment, more intensive Thal + bortezomib regimens could be explored to rescue higher numbers of patients.

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results